Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 37

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Oct 7, 2023; 29(37): 5327-5338
Published online Oct 7, 2023. doi: 10.3748/wjg.v29.i37.5327

Full Size Figure Download Figure

Figure 6 Adverse events with semaglutide. A: Gastrointestinal related side effects; B: Serious adverse events. 95%CI: 95% confidence intervals.

Citation: Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338
URL: https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i37.5327

Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338 [PMID: 37899788 DOI: 10.3748/wjg.v29.i37.5327]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.